Health and Fitness Health and Fitness
Mon, August 9, 2010
[ Mon, Aug 09th 2010 ] - Market Wire
Fibrocell Science, Inc. Submits Clinical Study Re .. g Administration for Phase II/III Trial of Azfice
[ Mon, Aug 09th 2010 ] - Market Wire
Pluristem's PLX Cells Found to Be Effective in Treating Neuropathic and Inflammatory Pain
[ Mon, Aug 09th 2010 ] - Market Wire
Alnylam Scientists and Collaborators Report Significant New Advances in RNAi Delivery
[ Mon, Aug 09th 2010 ] - Market Wire
Clinical Data, Inc. Reports First Quarter Fiscal Year 2011 Operational and Financial Results
[ Mon, Aug 09th 2010 ] - Market Wire
GTx, Inc. Reports Second Quarter 2010 Corporate Results
[ Mon, Aug 09th 2010 ] - Market Wire
WellCare Announces Securities Class Action Settlement
Fri, August 6, 2010
[ Fri, Aug 06th 2010 ] - Market Wire
Biogen Idec, Eastman Kodak, Morgan Stanley, Goldman Sachs and Allstate Corporation
[ Fri, Aug 06th 2010 ] - Market Wire
Chemed Corporation Increases Quarterly Dividend
[ Fri, Aug 06th 2010 ] - Market Wire
Spectral Molecular Imaging Inc. Chief Executive Officer Featured as a Guest on MoneyTV This Week
[ Fri, Aug 06th 2010 ] - Market Wire
Lannett Receives FDA Approval for Ondansetron Injection USP, 2 mg/mL Single-Dose Vials
[ Fri, Aug 06th 2010 ] - Market Wire
Medtronic Completes Enrollment in Clinical Study of Complete SE® (Self-Expanding) Vascular Stent
[ Fri, Aug 06th 2010 ] - Market Wire
El sistema PureGrafta" de Cytori recibe la aproba .. los procedimientos de injertos de tejido adiposo
[ Fri, Aug 06th 2010 ] - Market Wire
Das PureGrafta"-System von Cytori erhlt europische Zulassung fr Fetttransplantationsverfahren
[ Fri, Aug 06th 2010 ] - Market Wire
Il sistema PureGrafta" di Cytori riceve l'approva .. one europea per le procedure di innesto di grasso
[ Fri, Aug 06th 2010 ] - Market Wire
Health Net Federal Services Sponsors AMVETS 2010 Symposium for 21st Century Veterans
[ Fri, Aug 06th 2010 ] - Market Wire
Opexa Therapeutics Reports Second Quarter 2010 Financial Results
[ Fri, Aug 06th 2010 ] - Market Wire
Labopharm to present at Canaccord Genuity 30th Annual Growth Conference
[ Fri, Aug 06th 2010 ] - Market Wire
Notice of Medical Facilities Corporation';s Fisca .. Second Quarter Financial Results Conference Call
[ Fri, Aug 06th 2010 ] - Market Wire
Emeritus and Blackstone Joint Venture Acquires 132 Sunwest Communities
[ Fri, Aug 06th 2010 ] - Market Wire
UnitedHealth Group Announces New Initiatives to E .. an Adoption of EHRs That Meet Federal aMeaningful
[ Fri, Aug 06th 2010 ] - Market Wire
First Patient Treated with Medtronica?s Valiant® Thoracic Stent Graft in Aortic Dissection Trial
[ Fri, Aug 06th 2010 ] - Market Wire
Cardiovascular Systems to Webcast Fiscal 2010 Fou .. -Year Earnings Conference Call Tuesday, August 10
[ Fri, Aug 06th 2010 ] - Market Wire
Aetna Announces Expanded Support of Health Information Technology
[ Fri, Aug 06th 2010 ] - Market Wire
Alkermes Reports First Quarter Fiscal 2011 Financial Results
[ Fri, Aug 06th 2010 ] - Market Wire
Ironwood Pharmaceuticals Provides Second Quarter 2010 Investor Update
[ Fri, Aug 06th 2010 ] - Market Wire
Exelixis Announces Second Quarter 2010 Financial Results
[ Fri, Aug 06th 2010 ] - Market Wire
Cooper Announces Release Date for Third Quarter 2010
[ Fri, Aug 06th 2010 ] - Market Wire
RXi Pharmaceuticals to Host Second Quarter 2010 Conference Call on Wednesday, August 11, 2010
[ Fri, Aug 06th 2010 ] - Market Wire
InSite Vision Reports Second Quarter 2010 Financial Results
[ Fri, Aug 06th 2010 ] - Market Wire
Exelixis Announces August 12 Webcast of Presentat .. e Canaccord Genuity 30th Annual Growth Conference

Exelixis Announces August 12 Webcast of Presentation at the Canaccord Genuity 30th Annual Growth Conference


Published on 2010-08-06 04:27:07 - Market Wire
  Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the companya™s vice president of investor relations and corporate communications, will present at the Canaccord Genuity 30th Annual Growth Conference at 10:30 a.m. EDT / 7:30 a.m. PDT on Thursday, August 12, 2010 in Boston. Mr. Butler will discuss the companya™s corporate strategy, development pipeline and financial outlook, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors and Media at [ http://www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixisa™ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the companya™s web site at [ http://www.exelixis.com ].

Exelixis and the Exelixis logo are registered U.S. trademarks.

Contributing Sources